

1	Deve	lopment	t and	valid	dati	on c	of a	high	throug	hpu	t
---	------	---------	-------	-------	------	------	------	------	--------	-----	---

Neisseria gonorrhoeae genotyping me	neth	od
-------------------------------------	------	----



15 Running title: A high throughput method for Gonococcus genotyping



Abstract

29

30

32

33

34

35

36

37

39

40

42

43

44

45

46

Background

31 Neisseria gonorrhoeae genotyping by whole-genome sequencing (WGS) is

expensive for a large sample set, a less expensive and more efficient

genotyping method is required. We developed a high-throughput genotyping

method for N. gonorrhoeae to improve molecular epidemiological typing and

antimicrobial-resistant identification in N. gonorrhoeae antimicrobial

susceptibility surveillance.

Methods

We used multiplex-tailed PCR to amplify and sequence 15 alleles from

multilocus sequence typing (MLST), N. gonorrhoeae multiantigen sequence

typing (NG-MAST), and *N. gonorrhoeae* sequence typing for antimicrobial

41 resistance (NG-STAR). After indexing-PCR, we sequenced the DNA library

using the MiSeg platform (Illumina). Sequencing reads were de novo assembly

or constructing consensus sequences of alleles, then assigned sequence type.

We used 54 previously characterized strains of N. gonorrhoeae and WGS data

to validate our method.

Results

48

49

50

51

52

53

54

55

56

57

58

59

The allele identification results of MLST and NG-STAR in all strains agreed with the draft WGS. However, in NG-MAST, only 35 strains agreed. Disagreement was found in the NG-MAST of porB in 15 strains and of tbpB in seven strains. QRDR analysis perfectly predicted levofloxacin resistance. But was less successful in predicting reduced susceptibility or resistance phenotype to penicillin G, cefixime, or ceftriaxone using penA, porB, ponA, or mtrR alleles. **Conclusions** The successful performance in MLST and NG-STAR of our method was validated in this study. This method may be useful for large-scale genotyping for N. gonorrhoeae surveillance in a cost- and labor-saving manner. Phenotypic prediction of antimicrobial susceptibility by combining multiple alleles may be necessary for other than fluoroquinolones.

Introduction

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

The World Health Organization (WHO) estimated that there were 87 million new global cases of gonorrhea in 2016¹. Furthermore, the increasing frequency of antimicrobial resistant (AMR) Neisseria gonorrhoeae, the bacterium that causes gonorrhea, is a serious public health concern^{2,3}. Historically, resistance to penicillin G, fluoroquinolones, oral cephalosporins, ceftriaxone, and azithromycin has been problematic in the treatment of gonorrhea⁴. Ceftriaxone, an extended-spectrum cephalosporin or combination with azithromycin, are used as a first-line option for treating gonorrhea^{5,6}. However, in low- or middleincome countries, empiric therapy with inappropriate spectrum or dose oral antimicrobial agents such as cefixime, levofloxacin, or azithromycin that are over-the-counter systems for symptom-based sexually transmitted infections may select for ceftriaxone- or azithromycin-resistant N. gonorrhoeae^{4,7-9}. Understanding the development and spreading manor of AMR N. gonorrhoeae and antimicrobial resistant mechanisms are important to guide the appropriate use of the treatment option of gonorrhea and to motivate the development of novel agents to circumvent resistance.

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

One of the predominant mechanisms leading to resistance to ceftriaxone is a reduced affinity of penicillin binding protein 2 that causes mosaic-like mutations to cephalosporins^{10,11}. In 2009, a high-level ceftriaxone-resistant N. gonorrhoeae strain reported in Japan called H041 and WHO X severely limited the ability to treat gonorrhea^{12,13}. The first failure with combination therapy with both ceftriaxone and azithromycin was reported in the United Kingdom in 2016¹⁴. Therefore, the clonal spread of high-level ceftriaxone resistance alone and combinational resistance to both ceftriaxone and azithromycin should be carefully monitored. Whole-genome sequencing (WGS) using a massive parallel sequencer (MPS) can simultaneously analyze multiple typing methods¹⁵, such as multilocus sequence typing (MLST)^{16,17}, N. gonorrhoeae multi-antigen sequence typing (NG-MAST)¹⁸, and *N. gonorrhoeae* sequence typing for antimicrobial resistance (NG-STAR) scheme for 7 alleles associated with cephalosporins, fluoroquinolones, penicillins, and macrolides¹⁹. WGS using MPS is widely used and allows for a comprehensive analysis, but its cost per strain is too expensive

for large-scale surveillance^{15,18,20,21}. Hence, a less expensive and more efficient AMR *N. gonorrhoeae* genotyping method is required.

To address this need, we developed and validated a high throughput method that takes full advantage of the features of the MiSeq (Illumina, San Diego, CA, USA) sequence length that is commonly used in the analysis of bacteria.

Materials and Methods

Primers and condition for multiplex-tailed PCR

The sequences of the two primer sets and the concentrations for multiplex-tailed PCR that amplifies 15 alleles of MLST, NG-MAST, and NG-STAR are shown in Table S1. The primer design was a consensus sequence referring the genome sequence data of the 14 WHO *N. gonorrhoeae* reference strains²¹. We prepared primers with a tail sequence added to the 5' end based on the 16S rRNA amplicon sequence preparation protocol from Illumina²². If the target region was longer than the MiSeq merged read (approximately 450 bp), it was amplified with two pairs of primers (left and right side) per region (Figure 1).

suspension in sterilized water by heating at 95°C for 15 minutes and then centrifuged. Primer concentrations were adjusted to ensure equal amplification efficiency for each allele, and validation was performed by quantitative PCR with KAPA SYBR FAST qPCR Master Mix (2x) (Nippon Genetics Co., Ltd., Tokyo, Japan). We used TaKaRa Ex Premier DNA Polymerase (TaKaRa Bio, Shiga, Japan) for multiplex-tailed PCR with an initial incubation at 94°C for 5 min, followed by 30 cycles at 98°C for 10 s, 50°C for 15 s, 68°C for 30 s, and then 68°C for 1 min. The left and right multiplex PCR products were then mixed and purified using Agencourt AMPure XP (Beckman Coulter, Inc., CA, USA).

Indexing-PCR and sequencing by MiSeg

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

For indexing-PCR, barcodes for multiplex sequencing by MiSeq were added to each sample of the multiplex PCR amplicon using the Nextera XT Index Kit v2 (Illumina, Inc., CA, USA) and 2X KAPA HiFi HotStart ReadyMix (Nippon Genetics Co., Ltd., Tokyo, Japan). Indexing-PCR was conducted at 95°C for 3 min, followed by 8 cycles of 95°C for 30 s, 55°C for 30s, 72°C for 30s, and then 72°C for 5 min. After purification, the pooled library was sequenced with 350-

bp/250-bp paired-end reads on the MiSeq platform using the MiSeq reagent kit v3 600 cycle kit (Illumina).

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Allele identification from the multiplex PCR amplicon sequencing data Figure 2 shows an internal analysis pipeline that was constructed from an opensource software installed on our laboratory server machine. The template DNAspecific sequence of each primer on read was trimmed using Trimmomatic v.0.39²³. Before SPAdes v.3.15.3²⁴ for *de novo* assembly, aligned reads to each allele database were determined by BBtools (https://jgi.doe.gov/data-andtools/software-tools/bbtools/). Subsequently, the identification allele number of the MLST, NG-MAST, and NG-STAR alleles was performed by similarity analysis using the Basic Local Alignment Search Tool (BLAST)²⁵. These allele sequence databases were obtained from PubMLST (https://pubmlst.org/organisms/neisseria-spp, September 2022). Short and partial gyrA and parC sequences were obtained by mapping them to reference sequences using the BWA sw option²⁶ and then determining the consensus sequences using Samtools²⁷. quinolone-resistance determining region (QRDR) analysis was performed by the PointFinder tool²⁸.

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Nucleotide sequence accession numbers

Strains for validation To validate our novel typing method for *N. gonorrhoeae*, we used 54 of 55 strains characterized by a draft WGS (one strain was excluded because of discrepancies between the published and our reanalyzed draft WGS data)²⁸. The strains contained eight MLST-ST, 38 NG-MAST-ST, 10 penA alleles, five mtrR alleles, seven porB alleles, two ponA and 23S rRNA gene alleles, and three QRDR mutation patterns detected in GyrA and ParC from translated gyrA and parC (Tables 2 and 3). Counting average sequence reads depth The multiplex-PCR amplicon sequence reads were mapped using the BWA "sw" option to each allele sequence obtained by de novo assembly. Then, the sequence depth in the BAM file was determined using the pileup function in BBtools (https://jgi.doe.gov/data-and-tools/software-tools/bbtools/).

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

The MiSeq sequencing reads were deposited in the National Center for Biotechnology Information (NCBI) under BioProject number PRJNA901191. The Sequence Read Archive (SRA) accession number of fastg data of each sample were from SRR22270692 to SRR22270746 and are shown in Table S2. **Results** Evaluating sequencing read depth of each allele The statistical range of the average sequence depth in all 15 alleles (porB for NG-MAST and NG-STAR was calculated as one) of each strain was as follows: mean = 425x-28,423x; median = 348x-28,320x; and standard deviation = 285x-17,901x. Sequence depth plots of each allele are shown in Figure 3. Validating our method using a draft WGS as a reference For the 54 strains of *N. gonorrhoeae* evaluated in our study, our novel typing method was in agreement with the draft WGS method using MiSeq in all alleles of MLST and NG-STAR (Tables 1 and 2). The NG-MAST results of 35 strains agreed with the draft WGS (Table 1). When evaluating the NG-MAST sequence

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

type (ST), only one strain (NG-MAST-ST6771) both agreed and disagreed with the draft WGS data (three agreements and one disagreement) (Table 1). Predicting antimicrobial resistance All strains harboring amino acid substitution patterns of S91F and D95G or S91F and D95N in GyrA were levofloxacin resistant (Table 2). Harboring a penA10.001 allele was associated with reduced susceptibility to cefixime but not to ceftriaxone. A strain with a penA169.001 allele was resistant to both cefixime and ceftriaxone. All strains harboring penA10.001, penA72.001, penA106.001, penA150.001, penA168.001, penA169.001, mtrR1, mtrR33, porB8, porB10, porB11, porB12, porB24, and ponA1 alleles showed resistance or reduced susceptibility to penicillin G. We did not observe an association between the 23S rRNA allele and azithromycin susceptibility. Characterizing the disagreement with the draft WGS We identified two causes of disagreement in *porB* allele detection (Table 3). First, for 13 of 15 strains, the BLAST analysis results for detecting an exact match allele were confounded by variable allele lengths in the NG-MAST

database (unlike the MLST database) leading to ambiguity. Second, we detected a single nucleotide difference at different positions in 2 of the 15 strains (TUM15755 and TUM15777).

We also determined two causes of disagreement in *tbpB* allele detection (Table 4). First, there were between two and seven mismatches in multiple *tbpB* PCR primers among five of the seven strains, which prevented the acquisition of *tbpB* contigs for these strains. Second, we found that the contig of *tbpB* was divided into two contigs in these seven strains.

Discussion

The successful performance of MLST and NG-STAR of our developed high-throughput typing method was validated in this study. By allowing the analysis of a large number of *N. gonorrhoeae* strains concurrently, this method is both cost-effective and efficient. Furthermore, this method can potentially be used for typing *N. gonorrhoeae* and predicting AMR phenotype without culture from gonorrhea patients because of the PCR amplification specificity of each allele.

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

Although this method is not intended to evaluate all aspects of *N. gonorrhoeae*, it will likely be a valuable tool in large-scale AMR N. gonorrhoeae surveillance. Even though allelic analysis of MLST and NG-STAR was an exact match, NG-MAST did not produce the expected results with a small number of strains. There are several reasons that may explain this discrepancy. First, false higher than expected similarity scores for the allele were calculated by the BLAST analysis, which was the primary cause of the poor performance for the porB alleles in our study. These false higher similarity scores are likely due to the inconsistent lengths of the sequences registered in the NG-MAST database. A single nucleotide difference in a longer sequence will result in a higher similarity score than an exact match of a shorter sequence. Second, the porB disagreement in TUM15755 and TUM15777 is likely related to accidental nucleotide amplification errors in the multiplex-tailed PCR. The sequencing depth of porB was sufficient (more than 100x, Figure 3), so it is unlikely that sequencing errors were the cause. There is an option to use PCR enzyme with higher proofreading performance to prevent sequence amplification error in PCR, but at the risk that a slight primer sequence mismatch could result in a

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

significant decrease in amplification reaction efficiency. Third, two types of poor contig formation at the tbpB allele may be due to primer mismatches against the allele and its surrounding sequences in the affected strains that resulted in inefficient PCR amplification. This indirectly demonstrates the low conservation of the allele sequence. This is not surprising because although NG-MAST has a higher discrimination power than MLST, it makes primer design difficult to amplify all alleles. Recently, a novel AMR N. gonorrhoeae was reported without NG-MAST analysis²⁹, suggesting that NG-MAST may no longer be necessary in typing N. gonorrhoeae. We believe that WGS, not NG-MAST, is required for high resolution gonococcal transmission analysis³⁰. Because Japan has been an epicenter for AMR N. gonorrhoeae^{12,15,31-34}, it is appropriate to use Japanese strains to validate our typing methodology. However, since the validation of the primer region mismatch is insufficient, it may be necessary to update multiplex-tailed PCR primers and that PCR conditions while using this method in the future. We are in process of applying and analyzing this method to a historical collection constructed by 220 strains

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

isolated in Japan between 1972 and 2005. The preliminary results have been mostly favorable (manuscript in preparation). Notably, this method of NG-STAR for *gyrA* and *parC* only targets a narrow sequence around the QRDRs and thus does not allow for allele identification of gyrA and parC. Because the goal of NG-STAR is to detect mutations that contribute to AMR, the allele number does not necessarily have to be identifiable. The idea behind this is to keep the number of PCR products as small as possible to minimize the vulnerability of the multiplex-tailed PCR. If long read sequencers become available, the vulnerability of this method would be reduced as the multiplex-tailed PCR, which is currently divided into left and right assays, could be integrated into a single assay. In conclusion, we have developed a cost- and labor-saving high throughput N. gonorrhoeae genotyping method to add molecular epidemiological information to strains collected by AMR N. gonorrhoeae surveillance. By avoiding the sequencing of unnecessary regions in the three schemes, this method has

succeeded in increasing the number of strains that can be analyzed in one

MiSeq assay by approximately 5-fold compared with that obtained by WGS.

This method will be valuable in AMR N. gonorrhoeae as it is suitable for initial

analyses and can quickly identify new strains for subsequent WGS analysis.

Acknowledgment

270

271

272

273

274

275

277

278

279

280

This research was supported in part by AMED under Grant Numbers

276 JP15fk0108014h0001, JP18fk0108062j0001, and JP21fk0108605j0001.

Table 1. MLST and NG-MAST agreement in our novel typing method

versus draft whole-genome sequencing

MLST, multilocus sequence typing; NG-MAST, N. gonorrhoeae multi-antigen

281 sequence typing

		Novel typi	ng method vs.		
		MiSeq draft whole-genome sequencing			
Target	Sequence type	Agreement	Disagreement		
MLST	1579	6	0		
	1594	3	0		
	1597	1	0		
	1901	19	0		
	7359	11	0		
	7360	1	0		
	7827	1	0		
	15378	1	0		
	Total	54	0		

NO MACE	-	4
NG-MAST 24		1
140		0
151		0
221		0
239		1
295		0
342		0
370		0
392		0
401		0
401		0
418		1
533		1
568		0
588		0
654		3
676		1
677		1
677		0
679		4
680		0
703		0
106		0
131		0
141		0
141		1
142		0
142		1
155	01 1	0
155	26 0	1
155	28 0	1
180		0
196	19 1	0
196	20 1	0
196	21 1	0
196	22 0	1

Total	35	19
19706	1	0
19623	0	1

threonine; V, valine; Y, tyrosine.

Table 2. Validation of NG-STAR by our novel typing method versus draft whole-genome sequencing and antimicrobial resistant phenotype prediction

a Relationship between alleles and antimicrobial resistant phenotype: penA,
penicillin G reduced susceptibility (>0.25 mg/L) / cefixime reduced susceptibility
(>0.125 mg/L) / ceftriaxone reduced susceptibility (>0.125 mg/L); 23S rRNA,
azithromycin non-susceptible (>1 mg/L); mtrR, porB and ponA, penicillin G
reduced susceptibility (>0.25 mg/L); GyrA and ParC, levofloxacin resistant (>1
mg/L)¹⁵. NG-STAR, N. gonorrhoeae sequence typing for antimicrobial
resistance; a, according to NG-STAR metadata; Del, deletion; amino acid
abbreviations: A, alanine; D, aspartic acid; E, glutamic acid; F, phenylalanine;
G, glycine; K, lysine; L, leucine; N, asparagine; P, proline; S, serine; T,

			Novel typing method vs MiSeq draft whole genome sequencing	g method vs	
			sequ		
		Characteristics			Number of strains
.	Allele	of the		.	with antimicrobial
Allele (length)	number	translated	Agreement	Disagreement	resistant phenotype
		allele to AMR ^a			
A	4 004	Type I Non-	4	0	0.40.40
penA	1.001	Mosaic	4	0	0/0/0
(1,745 - 1,752	0.000	Type II Non-	44	0	4.10.10
bp)	2.002	Mosaic; A517G	11	0	4/0/0
		Type V Non-			
	5.002	mosaic; A517G,	2	0	2/0/0
		G543S			
		Type X Mosaic;		_	
	10.001	N513Y	18	0	18 / 18 / 0
		Type XXXIV			
	34.001	Mosaic; N513Y	5	0	5/3/0
		Type 72 Mosaic;			
	72.001	N513Y	8	0	8/8/0
		Type 106 Non-			
	106.001	Mosaic; A517G,	1	0	1/0/0
		G543S			
		Type 150 Semi-			
	150.001	Mosaic; A517G	3	0	3/0/0
		G543S			
		Type 168			
	168.001	Mosaic; A501V,	1	0	1/1/0
		N513Y			
		Type 169			
	169.001	Mosaic; A311V,	1	0	1/1/1
		N513Y		-	
	Total		54	0	31 / 1
mtrR	1	-35A Del	25	0	25
(643 – 719 bp)	4	Wild type	5	0	1

	33	Wild type	12	0	12
	42	A39T	11	0	5
	304	A39T	1	0	0
•	Total		54	0	43
porB	8	G120K, A121D	14	0	14
(30 bp)	10	G120K, A121D	1	0	1
	11	G120K, A121N	16	0	16
	12	G120K, A121G	1	0	1
	14	porB1a	1	0	0
	24	G120N, A121N	1	0	1
	100	Wild Type	20	0	10
	Total		54	0	43
ponA	1	L421P	36	0	36
(75 bp)	100	Wild type	18	0	7
·	Total		54	0	43
23S rRNA gene	8	Wild type	1	0	0
(566 - 570 bp)	100	Wild type	53	0	1
·	Total		54	0	1
GyrA	NA	S91F and D95G	27	0	27
	NA	S91F and D95N	12	0	12
	NA	Wild type	15	0	0
•	Total		54	0	39
ParC	NA	S88P	11	0	11
	NA	E91G	1	0	1
	NA	Wild type	42	0	27
	Total		54	0	39

Table 3. Cause of disagreement in NG-MAST of porB allele with draft

whole-genome sequence

298

299

300

Strain	Expected porB	Detected porB	Detection results	
ID	allele (draft	allele (top hit by	for the top hit	Causes of false allele detection
(TUM)	WGS)	BLAST)	allele	
45750	400	44047	Single nucleotide	porB 182 is three bases shorter on the 3' end
15752	182	11317	mismatch	than porB 11317 in the NG-MAST database
45755	4000	4000	Single nucleotide	Libertados da DOD annos
15755	4028	4028	mismatch	Likely due to PCR error
15762	206	11889	Single nucleotide	porB 206 is three bases shorter on the 3' end
15762	200	11009	mismatch	than porB 11889 in the NG-MAST database
			Single nucleotide	porB 2569 is three bases shorter on the 3'
15763	2569	12073	mismatch	end than porB 12073 in the NG-MAST
			mismatch	database
			Single nucleotide	porB 3854 is three bases shorter on the 3'
15767	3854	11337	mismatch	end than porB 11337 in the NG-MAST
			mismatch	database
			Single nucleotide	porB 4033 is three bases shorter on the 3'
15770	4033	11424	mismatch	end than porB 11424 in the NG-MAST
			mismatori	database
			Single nucleotide	porB 3854 is three bases shorter on the 3'
15775	3854	11337	mismatch	end than porB 11337 in the NG-MAST
			manatori	database
15777	4061	9083	Single nucleotide	Likely due to PCR error
10111	1001	0000	mismatch	Elitory and to 1 of tollow
			Single nucleotide	porB 3854 is three bases shorter on the 3'
15778	3854	11337	mismatch	end than porB 11337 in the NG-MAST
				database
15782	206	11889	Single nucleotide	porB 206 is three bases shorter on the 3' end
			mismatch	than porB 11889 in the NG-MAST database
			Single nucleotide	porB 4033 is three bases shorter on the 3'
15790	4033	11424	mismatch	end than porB 11424 in the NG-MAST
				database
15793	11399	4069	Single nucleotide	porB 11399 is six bases shorter on the 3' end
	-		mismatch	than porB 4069 in the NG-MAST database

15798	4033	11424	Single nucleotide mismatch	porB 4033 is three bases shorter on the 3' end than porB 11424 in the NG-MAST database
15796	4033	11424	Single nucleotide mismatch	porB 4033 is three bases shorter on the 3' end than porB 11424 in the NG-MAST database
15794	2547	11165	Single nucleotide mismatch	porB 2547 is three bases shorter on the 3' end than porB 11165 in the NG-MAST database

Table 4. Primer mismatch disagreement of the tbpB allele between NG-

MAST and the draft whole-genome sequence

			Number of mismatches on primers against				
			MiSeq draft WGS data				
Strain ID (TUM)	Expected tbpB allele (draft WGS)	Detection results	left (forward)	left (reverse)	right (forward)	right (reverse)	
15752	21	Contig divided into two No contig	0	1	0	0	
15756	1365	generation in tbpB	0	6	7	5	
15759	27	No contig generation in tbpB	0	0	2	5	
15764	2532	No contig generation in tbpB	5	6	5	5	

		No contig					
15782	2528	generation in	0	2	5	0	
		tbpB					
		No contig					
15789	1127	generation in	0	4	3	2	
		tbpB					
45704	21	Contig divided	0	1 0	0	0	
15794	۷۱	into two	U		0		

Figure legends

308

309

310

311

- Figure 1: Model of MiSeq sequencing library preparation for MLST, NG-
- 313 MAST, and NG-STAR by multiplex PCR
- 314 Multiplex-tailed PCR for target region amplification. A.
- 315 Design the primers for the left and right sides in the same arrangement for all 316 target alleles. There is a common tail sequence on the 5' side of the primers of 317 the multiplex PCR followed by indexing-PCR (the slanted part of the primer). To 318 avoid amplification by Left Rv and Right Fw primers, multiplex PCR for the left-319 and right-side primers is performed separately.

320 B. Indexing-PCR for adding the index sequence by PCR. 321 322 323 Figure 2: Read data analysis workflow MiSeq read data of multiplex PCR amplicon sequencing was analyzed by a de 324 325 novo assembly-based workflow. 326 327 Figure 3. Sequence depth on each allele 328 Sequence depth of our novel method using MiSeq is shown as a box plot. The 329 horizontal line in the box indicates the median, the upper end indicates the third 330 quartile, and the lower end indicates the first quartile. The upper end of the 331 whisker is drawn to the largest data point within 1.5× of the interquartile range 332 (IQR) from the third quartile, while the lower end of the whisker is drawn to the smallest value within 1.5× of the IQR from the first quartile. This boxplot was 333 334 generated by R ggplot2. 335

Reference

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

1. World Health Organization (WHO). Report on global sexually transmitted infection surveillance, 2018. 2018. Available at: https://www.who.int/publications/i/item/9789241565691 [verified January 2023]. 2. Barbaric J, Kuchukhidze G, Seguy N, et al. Surveillance and epidemiology of syphilis, gonorrhoea and chlamydia in the non-European Union countries of the World Health Organization European Region, 2015 to 2020. Euro Surveill 2022; **27**: 2100197. 3. Unemo M, Lahra MM, Cole M, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health 2019; 16: 412-25. 4. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014; 27: 587-613. 5. Seña AC, Bachmann L, Johnston C, et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics,

354

355

356

357

358

359

360

361

362

363

364

365

366

367

Zambia. BMC Infect Dis 2022; 22: 688.

therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis 2020; 20: e181-91. 6. World Health Organization (WHO). WHO guidelines for the treatment of Neisseria gonorrhoeae. 2016. Available at: https://www.who.int/publications/i/item/9789241549691 [verified January 2023]. 7. Garrett NJ, McGrath N, Mindel A. Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? Sex Transm Infect 2017; 93: 4-5. 8. World Health Organization (WHO). Guidelines for the management of symptomatic sexually transmitted infections. 2021. Available at: https://www.who.int/publications/i/item/9789240024168 [verified January 2023]. 9. Sarenje KL, Ngalamika O, Maimbolwa MC, Siame A, Munsaka SM, Kwenda G. Antimicrobial resistance of *Neisseria gonorrhoeae* isolated from patients attending sexually transmitted infection clinics in Urban Hospitals, Lusaka,

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

10. Ohnishi M, Watanabe Y, Ono E, et al. Spread of a chromosomal cefiximeresistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob Agents Chemother 2010; **54**: 1060–7. 11. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006; 50: 3638-45. 12. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55: 3538-45. 13. Unemo M, Golparian D, Sánchez-Busó L, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother 2016; 71: 3096–108. 14. Fifer H, Natarajan U, Jones L, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 2016; 374: 2504-6.

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

15. Hanao M, Aoki K, Ishii Y, Shimuta K, Ohnishi M, Tateda K. Molecular characterization of Neisseria gonorrhoeae isolates collected through a national surveillance programme in Japan, 2013: evidence of the emergence of a ceftriaxone-resistant strain from a ceftriaxone-susceptible lineage. J Antimicrob Chemother 2021; 76: 1769-75. 16. Viscidi RP, Demma JC. Genetic diversity of Neisseria gonorrhoeae housekeeping genes. J Clin Microbiol 2003; 41: 197–204. 17. Bennett JS, Jolley KA, Sparling PF, et al. Species status of Neisseria gonorrhoeae: evolutionary and epidemiological inferences from multilocus sequence typing. BMC Biol 2007; 5: 35. 18. Martin IMC, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189: 1497-505. 19. Demczuk W, Sidhu S, Unemo M, et al. Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance, a novel antimicrobial resistance multilocus typing scheme for tracking global dissemination of N. gonorrhoeae strains. J Clin Microbiol 2017; 55: 1454-68.

402 20. Unemo M, Lahra MM, Escher M, et al. WHO global antimicrobial resistance 403 surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational 404 study. The Lancet Microbe 2021; 2: e627–36. 405 21. Wang F, Liu J-W, Li Y-Z, et al. Surveillance and molecular epidemiology of 406 Neisseria gonorrhoeae isolates in Shenzhen, China, 2010–2017. Journal of 407 Global Antimicrobial Resistance 2020; 23: 269-74. 408 22. Illumina. 16S Metagenomic Sequencing Library Preparation. 2013. 409 Available at: 410 https://support.illumina.com/documents/documentation/chemistry documentatio 411 n/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf [verified January 412 2023]. 413 23. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina 414 sequence data. Bioinformatics 2014; 30: 2114-20. 415 24. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly 416 algorithm and its applications to single-cell sequencing. J Comput Biol 2012; 19:

417

455-77.

- 418 25. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment
- 419 search tool. *J Mol Biol* 1990; **215**: 403–10.
- 420 26. Li H, Durbin R. Fast and accurate short read alignment with Burrows-
- Wheeler transform. *Bioinformatics* 2009; **25**: 1754–60.
- 422 27. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format
- 423 and SAMtools. *Bioinformatics* 2009; **25**: 2078–9.
- 424 28. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM.
- 425 PointFinder: a novel web tool for WGS-based detection of antimicrobial
- resistance associated with chromosomal point mutations in bacterial pathogens.
- 427 *J Antimicrob Chemother* 2017; **72**: 2764–8.
- 428 29. Berçot B, Caméléna F, Mérimèche M, et al. Ceftriaxone-resistant, multidrug-
- resistant Neisseria gonorrhoeae with a novel mosaic penA-237.001 gene,
- 430 France, June 2022. Eurosurveillance 2022; **27**: 2200899.
- 431 30. Quainoo S, Coolen JPM, van Hijum SAFT, et al. Whole-genome sequencing
- of bacterial pathogens: the future of nosocomial outbreak analysis. *Clin*
- 433 *Microbiol Rev* 2017; **30**: 1015–63.

435

436

437

438

439

440

441

442

443

444

445


446

447

Chemother 2016; 60: 4339-41.

31. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46: 3744-9. 32. Ito M, Deguchi T, Mizutani K-S, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005; 49: 137-43. 33. Shimuta K, Watanabe Y, Nakayama S-I, et al. Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan. BMC Infect Dis 2015; 15: 378. 34. Nakayama S-I, Shimuta K, Furubayashi K-I, Kawahata T, Unemo M, Ohnishi M. New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents

Figure 1



B. Indexing-PCR




Figure 2




Figure 3

